iFAST Diagnostics Limited, a Whiteley, Hampshire-based developer of rapid antimicrobial susceptibility testing technology, has closed a $6.7 million funding round announced in May 2026.
The round was led by Meridian Health Ventures, with continued participation from existing backers including QantX, RAW Ventures and OKG Capital, alongside members of Cambridge Capital Group. The company also disclosed £2.1 million in non-dilutive loan funding from Innovate UK.
iFAST said the new funding will support its commercial rollout in the UK, help secure EU approval, and accelerate its clinical and regulatory programme for US FDA approval. The company described the round as oversubscribed and said total investment to date has now reached £12 million.
The raise highlights continued investor interest in diagnostics platforms aimed at addressing antimicrobial resistance, as healthcare systems seek faster tools to guide treatment decisions.
The round was led by Meridian Health Ventures, with continued participation from existing backers including QantX, RAW Ventures and OKG Capital, alongside members of Cambridge Capital Group. The company also disclosed £2.1 million in non-dilutive loan funding from Innovate UK.
iFAST said the new funding will support its commercial rollout in the UK, help secure EU approval, and accelerate its clinical and regulatory programme for US FDA approval. The company described the round as oversubscribed and said total investment to date has now reached £12 million.
The raise highlights continued investor interest in diagnostics platforms aimed at addressing antimicrobial resistance, as healthcare systems seek faster tools to guide treatment decisions.